You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News and reporting on ovarian cancer.
The firm presented initial study results from the test, which identifies six cancers, showing overall sensitivity at 86 percent and specificity of 95 percent.
The company's approach combines whole-genome sequencing, CRISPR, liquid biopsy, and gene therapy to target cancer cells with gene fusions.
In Science this week: deep-learning approach to detect cancer from blood samples, and more.
Accounting for polygenic background in conditions like hereditary breast cancer or Lynch syndrome can increase the accuracy of disease risk estimation.
Most of the disease risk carriers identified in the Healthy Nevada Project did not meet clinical guidelines for screening, according to the new analysis.
The targeted sequencing assay analyzes 12 genes and can be paired with the firm's BRCA gene testing kit.
An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.
RNA-seq of ascites from ovarian cancer patients uncovered shared inflammatory programs and suggested a JAK/STAT pathway inhibitor has antitumor activity.
Researchers identified secondary or incidental findings in just over 3 percent of the nearly 22,000 EMERGE III participants, who were profiled with a 109-gene panel.
The MAGENTA and ProGen trials showed that video-based and online education can increase the number of patients getting tested compared to traditional approaches.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.